Stocks · Health care · Pharmaceutical Preparations

Stoke Therapeutics, Inc.

STOK Clue Score65

United States Fiscal year ends December CIK 0001623526 Results filed 29 Oct 2026

Add to watchlist

By person

9 insiders · 81 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Adrian R. Krainer

Director

—

$3.90M (5) scheduled

−$3.90M

283,302

0.4390%

$7.65M

−30.0%

Barry Ticho

Chief Medical Officer

—

$1.92M (28) scheduled

−$1.92M

11,864

0.0184%

$320.22K

+377.4%

Edward M. MD Kaye

Director

—

$1.37M (14) scheduled

−$1.37M

124,557

0.1930%

$3.36M

+365.6%

Jonathan Allan

General Counsel & Corp Sec

—

$1.32M (22) scheduled

−$1.32M

20,598

0.0319%

$555.97K

+159.5%

Arthur Tzianabos

Director

—

$174.21K (1) scheduled

−$174.21K

31,339

0.0486%

$845.88K

−1.3%

Thomas Leggett

Chief Financial Officer

—

$147.14K (5)

−$147.14K

10,172

0.0158%

$274.56K

—

Jason Hoitt

Chief Patient Officer

—

$119.31K (5)

−$119.31K

10,276

0.0159%

$277.36K

+157.7%

Arthur A Levin

Director

—

$22.26K (1) scheduled

−$22.26K

4,237

0.0066%

$114.36K

—

Skorpios Trust entity

10% owner

—

3,906,181

6.05%

$105.43M

−56.1%

Stoke Therapeutics, Inc.

What the insiders did Net selling

By person